全文获取类型
收费全文 | 3665篇 |
免费 | 333篇 |
国内免费 | 83篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 109篇 |
妇产科学 | 73篇 |
基础医学 | 507篇 |
口腔科学 | 135篇 |
临床医学 | 556篇 |
内科学 | 750篇 |
皮肤病学 | 63篇 |
神经病学 | 225篇 |
特种医学 | 367篇 |
外国民族医学 | 1篇 |
外科学 | 404篇 |
综合类 | 75篇 |
预防医学 | 341篇 |
眼科学 | 23篇 |
药学 | 274篇 |
中国医学 | 6篇 |
肿瘤学 | 129篇 |
出版年
2021年 | 46篇 |
2019年 | 44篇 |
2018年 | 41篇 |
2017年 | 29篇 |
2016年 | 44篇 |
2015年 | 70篇 |
2014年 | 79篇 |
2013年 | 147篇 |
2012年 | 131篇 |
2011年 | 126篇 |
2010年 | 80篇 |
2009年 | 90篇 |
2008年 | 150篇 |
2007年 | 178篇 |
2006年 | 115篇 |
2005年 | 144篇 |
2004年 | 118篇 |
2003年 | 117篇 |
2002年 | 105篇 |
2001年 | 118篇 |
2000年 | 124篇 |
1999年 | 92篇 |
1998年 | 97篇 |
1997年 | 97篇 |
1996年 | 87篇 |
1995年 | 97篇 |
1994年 | 69篇 |
1993年 | 60篇 |
1992年 | 91篇 |
1991年 | 87篇 |
1990年 | 78篇 |
1989年 | 111篇 |
1988年 | 100篇 |
1987年 | 71篇 |
1986年 | 72篇 |
1985年 | 90篇 |
1984年 | 57篇 |
1983年 | 44篇 |
1982年 | 49篇 |
1981年 | 31篇 |
1980年 | 39篇 |
1979年 | 44篇 |
1978年 | 32篇 |
1977年 | 35篇 |
1976年 | 33篇 |
1975年 | 25篇 |
1972年 | 24篇 |
1971年 | 26篇 |
1970年 | 24篇 |
1968年 | 24篇 |
排序方式: 共有4081条查询结果,搜索用时 15 毫秒
1.
Coronary artery bypass grafts: visualization with MR imaging 总被引:1,自引:0,他引:1
2.
Donald B. Penzien PhD ; Frank Andrasik PhD ; Brian M. Freidenberg PhD ; Timothy T. Houle PhD ; Alvin E. Lake III PhD; Gay L. Lipchik PhD ; Kenneth A. Holroyd PhD ; Richard B. Lipton MD ; Douglas C. McCrory MD ; Justin M. Nash PhD ; Robert A. Nicholson PhD ; Scott W. Powers PhD ABPP ; Jeanetta C. Rains PhD ; David A. Wittrock PhD 《Headache》2005,45(S2):S110-S132
Guidelines for design of clinical trials evaluating behavioral headache treatments were developed to facilitate production of quality research evaluating behavioral therapies for management of primary headache disorders. These guidelines were produced by a Workgroup of headache researchers under auspices of the American Headache Society. The guidelines are complementary to and modeled after guidelines for pharmacological trials published by the International Headache Society, but they address methodologic considerations unique to behavioral and other nonpharmacological treatments. Explicit guidelines for evaluating behavioral headache therapies are needed as the optimal methodology for behavioral (and other nonpharmacologic) trials necessarily differs from the preferred methodology for drug trials. In addition, trials comparing and integrating drug and behavioral therapies present methodological challenges not addressed by guidelines for pharmacologic research. These guidelines address patient selection, trial design for behavioral treatments and for comparisons across multiple treatment modalities (eg, behavioral vs pharmacologic), evaluation of results, and research ethics. Although developed specifically for behavioral therapies, the guidelines may apply to the design of clinical trials evaluating many forms of nonpharmacologic therapies for headache. 相似文献
3.
M P Johnson X M Huang R Oberlender J F Nash D E Nichols 《European journal of pharmacology》1990,191(1):1-10
The present set of experiments was designed to examine the effects of extension of the alpha-methyl of p-chloroamphetamine (PCA) to an alpha-ethyl. Therefore, the alpha-ethyl homologue of PCA, 1-(4-chlorophenyl)-2-aminobutane (CAB), was compared to PCA in a number of pharmacological assays. CAB was 2-fold less potent than PCA at inhibiting synaptosomal uptake of [3H]5-hydroxytryptamine ([3H]5-HT), and 5-fold less potent at inhibiting uptake of [3H]dopamine ([3H]DA). In drug discrimination assays, CAB was approximately 3-fold less potent than PCA in animals trained to discriminate 3,4-methylenedioxymethamphetamine (MDMA) or its alpha-ethyl homologue, S-(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (S-(+)-MBDB), from saline. Monitoring with in vivo microdialysis, 10 mg/kg of PCA caused a large increase in extracellular DA and a significant decrease in 3,4-dihydroxyphenylacetic acid (DOPAC) in the striatum. In contrast, 11 mg/kg CAB caused no increase and 22 mg/kg CAB caused only a slight increase in extracellular DA. Both doses of CAB caused a decrease in extracellular DOPAC. The potential 5-HT neurotoxicity of CAB was examined by measuring monoamine and metabolite levels and [3H]paroxetine binding at one week following acute doses. A 10 mg/kg dose of PCA caused an 80% decrease in cortical and hippocampal serotonergic markers, while an equimolar dose of CAB decreased only hippocampal 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) levels. However, 22 mg/kg of CAB produced a 20-40% decrease in all serotonergic markers. Thus, extension of the alpha-alkyl significantly decreases the dopaminergic effects of PCA. The similar decrease in relative 5-HT neurotoxicity and the decreased ability to alter dopaminergic systems in vivo and in vitro supports the involvement of DA in the neurotoxicity of PCA. 相似文献
4.
5.
D. Chemla P. Démolis M. Thyrault D. Annane Y. Lecarpentier and JF Giudicelli 《Fundamental & clinical pharmacology》1996,10(4):393-399
Summary— The influence of local resistance and cardiac performance on peripheral blood acceleration was investigated in 14 healthy male volunteers. Steady and pulsatile flow was studied in the brachial and in the common carotid arteries, ie, two territories that exhibit marked differences in resistive characteristics. Instantaneous blood velocity (V), mean blood velocity (Vm ) and artery diameter (D) were evaluated at rest by an ultrasonic range-gated pulsed Doppler flowmeter using a double transducer probe, thus allowing the calculation of mean blood flow (Q). Mean local resistance (R) was obtained by dividing the mean arterial pressure by Q. The peak value of the local acceleration of the blood was obtained by computer-assisted calculation of the first derivative of instantaneous blood velocity (Gmax = +dV/dtmax ). Peak aortic blood acceleration (GAo) was simultaneously measured from the suprasternal notch using a pulsed Doppler velocity meter. In the brachial and the common carotid arteries, Gmax was of a similar magnitude (551 ±30 and 555 ± 44 cm/s2 , respectively) despite major differences in the respective D, Vm , Q and R values. In neither artery was there a relationship between Gmax and either resting Q or R. At the brachial artery level, Gmax was positively related to GAo ( r = 0.79, P = 0.0008). At the common carotid artery level, there was a weak, although non significant relationship between Gmax and GAo ( P = 0.08). Our results indicate that the local acceleration of peripheral blood flow in the brachial artery is related rather to upstream central impulse than to downstream hemodynamics, and suggest some regional differences in the hemodynamic determinants of the local acceleration of peripheral blood flow. 相似文献
6.
In a prospective, randomized, double-blind study, 49 patients underwent lumbar myelography using iotrol (24 patients) or metrizamide (25 patients). The diagnostic imaging adequacy of iotrol was comparable with that of metrizamide. After iotrol myelography, adverse reactions were fewer, less severe, and of shorter duration than were those following metrizamide myelography. Thirteen of 24 patients (54%) receiving iotrol reported some adverse reactions compared with 24 of 25 patients (96%) receiving metrizamide. Five moderate and one severe adverse reaction occurred in the group receiving iotrol. Fourteen moderate and eight severe adverse reactions occurred in the group receiving metrizamide. Thirty-eight patients underwent electroencephalography both before and after myelography (19 iotrol and 19 metrizamide). None of the EEGs obtained after iotrol myelography changed from baseline, while seven of the EEGs obtained after metrizamide myelography showed changes from baseline. Iotrol was judged superior to metrizamide as a contrast medium in this patient population. 相似文献
7.
8.
9.
10.
A comparison of pharmacological (amitriptyline HCL) and nonpharmacological (cognitive-behavioral) therapies for chronic tension headaches 总被引:1,自引:0,他引:1
K A Holroyd J M Nash J D Pingel G E Cordingley A Jerome 《Journal of consulting and clinical psychology》1991,59(3):387-393
Forty-one recurrent tension headache sufferers were randomly assigned to either cognitive-behavioral therapy (administered in a primarily home-based treatment protocol) or to amitriptyline therapy (with dosage individualized at 25, 50, or 75 mg/day). Cognitive-behavioral therapy and amitriptyline each yielded clinically significant improvements in headache activity, both when improvement was assessed with patient daily recordings (56% and 27% reduction in headache index, respectively), and when improvement was assessed with neurologist ratings of clinical improvement (94% and 69% of patients rated at least moderately improved, respectively). In instances where differences in treatment effectiveness were observed (headache index, somatic complaints, perceptions of control of headache activity), cognitive-behavioral therapy yielded somewhat more positive outcomes than did amitriptyline. Neither treatment, however, eliminated headache problems. 相似文献